Search results

...nofovir]] (Viread) under the brand name '''Truvada'''. A fixed-dose triple combination of emtricitabine, tenofovir and [[efavirenz]] (Sustiva, marketed by [[Brist Emtricitabine is indicated in combination with other [[antiretroviral]] agents for the treatment of HIV infection in adults. This indication is b

Lamivudine has been used for treatment of chronic [[hepatitis B]] at a lower dose than for treatment of [[HIV]]. It improves the seroconversion of e-antigen ...omer, now called Lamivudine. The drug's effectiveness for treating HIV in combination with AZT was discovered accidentally when a patient took Zidovudine secretl

...lead Sciences]] under the trade name '''Viread''', belongs to a class of [[antiretroviral drug]]s known as nucleotide analogue [[reverse transcriptase inhibitor]]s ( ...by the FDA on 12 July 2006 and is now available, providing a single daily dose for the treatment of HIV.

...mulation]] with a sub-therapeutic dose of [[ritonavir]], as a component of combination therapy to treat [[HIV]]/[[AIDS]]. The Kaletra formulation has also been us ...man Services|DHHS]].<ref name="dhhs">DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available f

...sing schedules, and therefore has the potential to increase adherence to [[antiretroviral]] therapy. Atripla is the first multi-class antiretroviral drug available in the United States and represents the first collaboration

...in reducing [[Polypharmacy|pill burden]] and in aiding compliance with the antiretroviral drug therapy. ...Administration]] on September 26, 1997, making it the thirteenth approved antiretroviral. It is marketed by [[GlaxoSmithKline]].

...e tablet, it reduces the [[pill burden]] and increases [[compliance]] with antiretroviral therapy. The drug has also found some potential as a preventative measure i Emtricitabine/tenofovir DF in combination with various boosted PIs was generally well tolerated by adults with HIV-1